Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Devices & Implants
- Sub-Industry: N/A
- Symbol: NYSE:GKOS
- CUSIP: N/A
- Web: www.glaukos.com
- Market Cap: $1.10843 billion
- Outstanding Shares: 34,434,000
- 50 Day Moving Avg: $36.29
- 200 Day Moving Avg: $36.29
- 52 Week Range: $28.72 - $52.49
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: -13.42
- Annual Revenue: $139.94 million
- Price / Sales: 7.92
- Book Value: $3.66 per share
- Price / Book: 8.80
- EBIDTA: $8.15 million
- Net Margins: -0.81%
- Return on Equity: 3.52%
- Return on Assets: 3.06%
- Current Ratio: 6.86%
- Quick Ratio: 6.42%
- Average Volume: 2.26 million shs.
- Beta: 1.31
- Short Ratio: 8.2
Frequently Asked Questions for Glaukos Corporation (NYSE:GKOS)
What is Glaukos Corporation's stock symbol?
Glaukos Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."
How were Glaukos Corporation's earnings last quarter?
Glaukos Corporation (NYSE:GKOS) posted its earnings results on Wednesday, March, 1st. The company reported $0.00 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.00 by $0.00. The business earned $33.17 million during the quarter, compared to analyst estimates of $29.49 million. Glaukos Corporation had a positive return on equity of 3.52% and a negative net margin of 0.81%. The company's quarterly revenue was up 63.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.07) EPS. View Glaukos Corporation's Earnings History.
When will Glaukos Corporation make its next earnings announcement?
Where is Glaukos Corporation's stock going? Where will Glaukos Corporation's stock price be in 2017?
7 analysts have issued twelve-month price targets for Glaukos Corporation's shares. Their forecasts range from $38.00 to $60.00. On average, they expect Glaukos Corporation's stock price to reach $51.33 in the next twelve months. View Analyst Ratings for Glaukos Corporation.
What are analysts saying about Glaukos Corporation stock?
Here are some recent quotes from research analysts about Glaukos Corporation stock:
- 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (9/20/2017)
- 2. Cantor Fitzgerald analysts commented, "Numbers out of the Way. Yes, 2Q17 revenue growth was impacted several factors: implementation of updated rates and commercial private payers (20% of the market) and sampling by a competitor. Yes, unfortunately these headwinds will remain in place for the rest of the year, coupled with the impact of the hurricanes (TX and FL represents 7% of overall sales). Accordingly, we have lowered our 2017 revenue estimate from $167 million to $158 million. If nothing else happened today, we would perhaps understand the outsized negative reaction (stock is down ~20% intraday)." (9/14/2017)
Who are some of Glaukos Corporation's key competitors?
Some companies that are related to Glaukos Corporation include Endologix (ELGX), Cerus Corporation (CERS), RTI Surgical (RTIX), Obalon Therptcs (OBLN), ConforMIS (CFMS), Second Sight Medical Products (EYES), Concepta PLC (CPT), Concepta PLC (FRI), Cyberonics (CYBX), HeartWare International (HTWR), St Jude Medical (STJ), Trivascular Technologies (TRIV) and Uroplasty (UPI).
Who are Glaukos Corporation's key executives?
Glaukos Corporation's management team includes the folowing people:
- William J. Link Ph.D., Independent Chairman of the Board
- Thomas William Burns, President, Chief Executive Officer and Director
- Joseph E. Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development
- Chris M. Calcaterra, Chief Commercial Officer and Chief Operating Officer
- L. Jay Katz, Chief Medical Officer
- Mark J. Foley, Independent Director
- David F. Hoffmeister, Independent Director
- Gilbert Kliman M.D., Independent Director
- Jonathan Todd Silverstein J.D., Independent Director
- Marc A. Stapley, Independent Director
When did Glaukos Corporation IPO?
(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Who owns Glaukos Corporation stock?
Glaukos Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (9.06%), Capital World Investors (7.96%), William Blair Investment Management LLC (6.31%), Vanguard Group Inc. (4.85%), Alliancebernstein L.P. (4.75%) and Gilder Gagnon Howe & Co. LLC (4.32%). Company insiders that own Glaukos Corporation stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos Corporation.
Who sold Glaukos Corporation stock? Who is selling Glaukos Corporation stock?
Glaukos Corporation's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Lord Abbett & CO. LLC, C WorldWide Group Holding A S, Russell Investments Group Ltd., American Century Companies Inc., Bank of Montreal Can, Numeric Investors LLC and Chartwell Investment Partners LLC. Company insiders that have sold Glaukos Corporation stock in the last year include Chris M Calcaterra, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Insider Buying and Selling for Glaukos Corporation.
Who bought Glaukos Corporation stock? Who is buying Glaukos Corporation stock?
Glaukos Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Koch Industries Inc., Bamco Inc. NY, Capital World Investors, Alliancebernstein L.P., Peregrine Capital Management LLC, Wells Fargo & Company MN and State Street Corp. Company insiders that have bought Glaukos Corporation stock in the last two years include Aimee S Weisner and Richard L Harrison. View Insider Buying and Selling for Glaukos Corporation.
How do I buy Glaukos Corporation stock?
Shares of Glaukos Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Glaukos Corporation's stock price today?
MarketBeat Community Rating for Glaukos Corporation (NYSE GKOS)MarketBeat's community ratings are surveys of what our community members think about Glaukos Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Glaukos Corporation stock can currently be purchased for approximately $32.19.
Earnings History for Glaukos Corporation (NYSE:GKOS)Earnings History by Quarter for Glaukos Corporation (NYSE GKOS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|3/1/2017||Q416||$0.00||$0.00||$29.49 million||$33.17 million||View||Listen|
|11/10/2016||Q316||($0.01)||$0.03||$27.21 million||$29.60 million||View||N/A|
|8/1/2016||Q216||($0.04)||$0.06||$24.45 million||$28.60 million||View||N/A|
|5/3/2016||Q116||($0.15)||$0.03||$18.77 million||$23.10 million||View||N/A|
|3/1/2016||Q415||($0.13)||($0.07)||$20.07 million||$20.28 million||View||N/A|
|11/10/2015||Q315||($0.17)||($0.07)||$17.93 million||$19.00 million||View||Listen|
Earnings Estimates for Glaukos Corporation (NYSE:GKOS)
Next Year EPS Consensus Estimate: $0.25 EPS
Dividend History for Glaukos Corporation (NYSE:GKOS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Glaukos Corporation (NYSE:GKOS)
Insider Ownership Percentage: 16.40%Insider Trades by Quarter for Glaukos Corporation (NYSE:GKOS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/7/2017||Thomas William Burns||CEO||Sell||73,788||$41.36||$3,051,871.68|| |
|9/5/2017||Orbimed Advisors Llc||Director||Sell||580,200||$38.73||$22,471,146.00|| |
|9/5/2017||Thomas William Burns||CEO||Sell||1,212||$41.25||$49,995.00|| |
|8/17/2017||Orbimed Advisors Llc||Director||Sell||325,000||$37.93||$12,327,250.00|| |
|3/14/2017||Orbimed Advisors Llc||Director||Sell||382,538||$45.33||$17,340,447.54|| |
|2/2/2017||Thomas William Burns||CEO||Sell||50,000||$42.58||$2,129,000.00|| |
|1/13/2017||Chris M Calcaterra||Insider||Sell||18,136||$40.01||$725,621.36|| |
|1/13/2017||Richard L Harrison||CFO||Sell||20,634||$40.00||$825,360.00|| |
|1/9/2017||Chris M Calcaterra||Insider||Sell||20,000||$38.02||$760,400.00|| |
|1/9/2017||Thomas William Burns||CEO||Sell||40,000||$37.60||$1,504,000.00|| |
|1/6/2017||Richard L Harrison||CFO||Sell||20,634||$35.58||$734,157.72|| |
|11/17/2016||William J Phd Link||Director||Sell||30,000||$33.78||$1,013,400.00|| |
|11/15/2016||Thomas William Burns||CEO||Sell||200,120||$33.68||$6,740,041.60|| |
|10/24/2016||Chris M Calcaterra||Insider||Sell||20,000||$36.01||$720,200.00|| |
|10/20/2016||Chris M Calcaterra||Insider||Sell||40,000||$34.76||$1,390,400.00|| |
|8/12/2016||Jonathan Silverstein||Director||Sell||292,938||$33.69||$9,869,081.22|| |
|8/3/2016||Orbimed Advisors Llc||Director||Sell||425,000||$30.59||$13,000,750.00|| |
|7/27/2016||Richard L Harrison||CFO||Sell||10,000||$35.01||$350,100.00|| |
|7/13/2016||Thomas William Burns||CEO||Sell||162,254||$30.07||$4,878,977.78|| |
|7/12/2016||Richard L Harrison||CFO||Sell||5,700||$30.00||$171,000.00|| |
|6/20/2016||Richard L Harrison||CFO||Sell||4,300||$30.00||$129,000.00|| |
|6/20/2016||Thomas William Burns||CEO||Sell||7,997||$30.00||$239,910.00|| |
|6/15/2016||Chris M Calcaterra||Insider||Sell||45,464||$28.46||$1,293,905.44|| |
|6/6/2016||Thomas William Burns||CEO||Sell||24,578||$25.16||$618,382.48|| |
|6/3/2016||Thomas William Burns||CEO||Sell||422||$25.00||$10,550.00|| |
|6/1/2016||Thomas William Burns||CEO||Sell||25,000||$23.90||$597,500.00|| |
|5/25/2016||Thomas William Burns||CEO||Sell||300||$25.00||$7,500.00|| |
|5/4/2016||Chris M Calcaterra||Insider||Sell||74,536||$24.40||$1,818,678.40|| |
|5/4/2016||Richard L Harrison||CFO||Sell||30,000||$24.59||$737,700.00|| |
|5/4/2016||Thomas William Burns||CEO||Sell||36,700||$24.67||$905,389.00|| |
|3/4/2016||Aimee S Weisner||Director||Buy||2,500||$16.03||$40,075.00|| |
|2/25/2016||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||70,000||$16.16||$1,131,200.00|| |
|12/31/2015||Richard L Harrison||CFO||Buy||1,388||$15.30||$21,236.40|| |
|11/12/2015||Aimee S Weisner||Director||Buy||2,500||$21.83||$54,575.00|| |
Headline Trends for Glaukos Corporation (NYSE:GKOS)
Latest Headlines for Glaukos Corporation (NYSE:GKOS)
Glaukos Corporation (GKOS) Chart for Sunday, September, 24, 2017